NCT03716908

Brief Summary

DFNA9 (Deafness Autosomal Dominant 9) is an autosomal dominant hereditary hearing loss which is associated with vestibular deterioration. The most recent genotype-phenotype correlation studies have been conducted more than 15 years ago. Meanwhile, emerging and valuable vestibular tests have been added to the vestibular test battery. These tests were not available at the time of the correlation studies. The aim of this study is to carry out a prospective cross-sectional study on symptomatic and presymptomatic affected carriers of the Pro51Ser (P51S) Coagulation Factor C Homology (COCH) mutation in order to correlate vestibular data using the complete vestibular test battery with the known data on hearing and vestibular function in relation to age.

Trial Health

77
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
70

participants targeted

Target at P25-P50 for all trials

Timeline
6mo left

Started Jun 2018

Longer than P75 for all trials

Geographic Reach
1 country

1 active site

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress93%
Jun 2018Nov 2026

Study Start

First participant enrolled

June 1, 2018

Completed
5 months until next milestone

First Submitted

Initial submission to the registry

October 19, 2018

Completed
4 days until next milestone

First Posted

Study publicly available on registry

October 23, 2018

Completed
1.3 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

February 15, 2020

Completed
6.8 years until next milestone

Study Completion

Last participant's last visit for all outcomes

November 30, 2026

Expected
Last Updated

October 28, 2021

Status Verified

August 1, 2021

Enrollment Period

1.7 years

First QC Date

October 19, 2018

Last Update Submit

October 27, 2021

Conditions

Outcome Measures

Primary Outcomes (2)

  • hearing threshold

    pure tone audiometry, decibel hearing loss (dB HL)

    1 year

  • video HIT

    video Head Impulse test, gain (eye movement versus head movement)

    1 year

Secondary Outcomes (7)

  • VEMP

    1 year

  • DHI questionnaire

    1 year

  • OS questionnaire

    1 year

  • ABC questionnaire

    1 year

  • EQ-5D-5L questionnaire

    1 year

  • +2 more secondary outcomes

Study Arms (2)

P51S+ group

Group 1 affected subjects (P51S+) Family member P51S mutation carrier interventions/ Questionnaire (DHI, OS, EQ-D5-5L, ABC) Pure Tone audiometry VNG vHIT c- and o-VEMP

P51S- group (healthy control)

Group 2: healthy control Family member P51S non-carrier interventions: Questionnaire (DHI, OS, EQ-D5-5L, ABC) Pure Tone audiometry VNG vHIT c- and o-VEMP

Eligibility Criteria

Age18 Years+
Sexall
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

all family pedigree in which at least one proband is carrying the Pr51Ser (P51S) mutation in the COCH gene that are known in three tertiary referral centers: University Hospital Antwerp, Maastricht University Medical Centre and Jessa Hospital Hasselt.

You may qualify if:

  • subject must be 18 year of older
  • subject is a family member of the family pedigree's proband(s) carrying a P51S COCH mutation

You may not qualify if:

  • subject is younger than 18 years
  • subject is not a family member of the pedigree's proband(s) carrying a P51S
  • subject cannot undergo investigations (medical and/or mental reasons)
  • subject is not willing to be enrolled into the study
  • subject suffers other concomitant middle or inner ear disease
  • subject has undergone middle ear or inner ear surgery
  • subject suffers other concomitant vestibular disease than DFNA9
  • subject has undergone vestibular surgery or other non-invasive vestibular treatment (gentamicin intratympanal injections for example)

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

University of Antwerp

Antwerp, 2650, Belgium

RECRUITING

Related Publications (2)

  • JanssensdeVarebeke SPF, Moyaert J, Fransen E, Bulen B, Neesen C, Devroye K, van de Berg R, Pennings RJE, Topsakal V, Vanderveken O, Van Camp G, Van Rompaey V. Genotype-Phenotype Correlation Study in a Large Series of Patients Carrying the p.Pro51Ser (p.P51S) Variant in COCH (DFNA9) Part II: A Prospective Cross-Sectional Study of the Vestibular Phenotype in 111 Carriers. Ear Hear. 2021 Nov-Dec 01;42(6):1525-1543. doi: 10.1097/AUD.0000000000001070.

  • JanssensdeVarebeke SPF, Moyaert J, Fransen E, Bulen B, Neesen C, Devroye K, van de Berg R, Pennings RJE, Topsakal V, Vanderveken O, Van Camp G, Van Rompaey V. Genotype-phenotype Correlation Study in a Large Series of Patients Carrying the p.Pro51Ser (p.P51S) Variant in COCH (DFNA9): Part I-A Cross-sectional Study of Hearing Function in 111 Carriers. Ear Hear. 2021 Nov-Dec 01;42(6):1508-1524. doi: 10.1097/AUD.0000000000001099.

Biospecimen

Retention: SAMPLES WITH DNA

blood samples for the genetic diagnosis of carriership of P51S COCH mutation

MeSH Terms

Conditions

Vestibular Diseases

Condition Hierarchy (Ancestors)

Labyrinth DiseasesEar DiseasesOtorhinolaryngologic Diseases

Central Study Contacts

sebastien PF JanssensdeVarebeke, MD

CONTACT

Vincent Van Rompaey, PhD, MD

CONTACT

Study Design

Study Type
observational
Observational Model
CASE CONTROL
Time Perspective
CROSS SECTIONAL
Target Duration
1 Year
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

October 19, 2018

First Posted

October 23, 2018

Study Start

June 1, 2018

Primary Completion

February 15, 2020

Study Completion (Estimated)

November 30, 2026

Last Updated

October 28, 2021

Record last verified: 2021-08

Data Sharing

IPD Sharing
Will not share

Locations